135 related articles for article (PubMed ID: 12813914)
1. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
Friedman HM
Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.
Lubinski JM; Jiang M; Hook L; Chang Y; Sarver C; Mastellos D; Lambris JD; Cohen GH; Eisenberg RJ; Friedman HM
J Virol; 2002 Sep; 76(18):9232-41. PubMed ID: 12186907
[TBL] [Abstract][Full Text] [Related]
3. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.
Lubinski JM; Lazear HM; Awasthi S; Wang F; Friedman HM
J Virol; 2011 Apr; 85(7):3239-49. PubMed ID: 21228231
[TBL] [Abstract][Full Text] [Related]
4. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
Awasthi S; Lubinski JM; Friedman HM
Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
[TBL] [Abstract][Full Text] [Related]
5. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.
Nagashunmugam T; Lubinski J; Wang L; Goldstein LT; Weeks BS; Sundaresan P; Kang EH; Dubin G; Friedman HM
J Virol; 1998 Jul; 72(7):5351-9. PubMed ID: 9620988
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
7. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
8. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor.
Lin X; Lubinski JM; Friedman HM
J Virol; 2004 Mar; 78(5):2562-71. PubMed ID: 14963159
[TBL] [Abstract][Full Text] [Related]
9. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
[TBL] [Abstract][Full Text] [Related]
10. Viral interference with antibody and complement.
Lubinski J; Nagashunmugam T; Friedman HM
Semin Cell Dev Biol; 1998 Jun; 9(3):329-37. PubMed ID: 9665870
[TBL] [Abstract][Full Text] [Related]
11. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
[TBL] [Abstract][Full Text] [Related]
14. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.
Vollstedt S; Franchini M; Alber G; Ackermann M; Suter M
J Virol; 2001 Oct; 75(20):9596-600. PubMed ID: 11559791
[TBL] [Abstract][Full Text] [Related]
16. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.
Judson KA; Lubinski JM; Jiang M; Chang Y; Eisenberg RJ; Cohen GH; Friedman HM
J Virol; 2003 Dec; 77(23):12639-45. PubMed ID: 14610186
[TBL] [Abstract][Full Text] [Related]
17. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease.
Saldanha CE; Lubinski J; Martin C; Nagashunmugam T; Wang L; van Der Keyl H; Tal-Singer R; Friedman HM
J Virol; 2000 Aug; 74(15):6712-9. PubMed ID: 10888608
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells.
Dingwell KS; Brunetti CR; Hendricks RL; Tang Q; Tang M; Rainbow AJ; Johnson DC
J Virol; 1994 Feb; 68(2):834-45. PubMed ID: 8289387
[TBL] [Abstract][Full Text] [Related]
20. Reducing Viral Inhibition of Host Cellular Apoptosis Strengthens the Immunogenicity and Protective Efficacy of an Attenuated HSV-1 Strain.
Xu X; He Y; Fan S; Feng M; Jiang G; Wang L; Zhang Y; Liao Y; Li Q
Virol Sin; 2019 Dec; 34(6):673-687. PubMed ID: 31506828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
